包装规格：

250mg 1g 5g 25g in glass bottle

产品简介：

Minocycline hydrochloride 是一种口服有效、能透过血脑屏障的半合成四环素类抗生素。Minocycline hydrochloride 是一种缺氧诱导因子 (HIF-1α) 抑制剂。Minocycline hydrochloride 具有抗癌(anti-cancer)，抗炎(anti-inflammatory) 和谷氨酸 (glutamate) 拮抗作用。Minocycline hydrochloride 降低谷氨酸神经传递，显示神经保护特性和抗抑郁作用。Minocycline hydrochloride 通过与细菌核糖体30S亚基结合，抑制细菌蛋白的合成，从而产生抑菌 (bacteriostatic) 作用。

溶解性：

溶于DMSO

储备液保存：

-80°C, 1 years; -20°C, 6 months

体内实验：

1、请依序添加每种溶剂： PBS
Solubility: 7.69 mg/mL (15.57 mM); Clear solution; Need ultrasonic

＜1mg/ml表示微溶或不溶。
圆创生科提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

体外研究：

Minocycline hydrochloride (0-100 μM, 24-72 h) suppresses proliferation and clonogenic activity of ovarian cancer cell-lines (OVCAR-3, SKOV-3 and A2780).
Minocycline hydrochloride (0-100 μM, 24-48 h)arrests cell cycle through inhibition of cyclins and suppression of DNA incorporation.
Minocycline hydrochloride (0-100 μM, 72 h) induces cell apoptosis in ovarian cancer cell lines.
Minocycline hydrochloride shows direct neuronal protection, and this mode of protection is likely to be associated with the preservation of mitochondrial integrity and cytochrome c, followed by the suppression of caspase-dependent as well as caspase-independent cell death.
Minocycline hydrochloride leads to suppression of Hypoxia-inducible factor (HIF)-1α accompanied by up-regulation of p53 protein levels and inactivation of AKT/mTOR/p70S6K/4E-BP1 pathway.

体内研究：

Minocycline hydrochloride (0-30 mg/kg, orally, daily for 4 weeks) suppresses OVCAR-3 tumor growth in female nude mice. Minocycline hydrochloride (IP) is an effective neuroprotective agent in animal models of cerebral ischemia when given in high doses intraperitoneally.
Minocycline hydrochloride (0-40 mg/kg, IP, once) significantly attenuats METH-induced hyperlocomotion and the development of behavioral sensitization in mice.
Minocycline hydrochloride (3 and 10 mg/kg, IV, once) is effective at reducing infarct size in a Temporary Middle Cerebral Artery Occlusion model (TMCAO).
Minocycline hydrochloride (3-10 mg/kg, IV, once) results in serum levels (at 3 mg/kg) similar to that achieved in humans after a standard 200 mg dose.
Minocycline hydrochloride attenuates ischemia-induced ventricular arrhythmias in rats. This effect may be associated with activations of PI3K/Akt signaling pathway, mitochondrial KATP channels and L-type Ca2+ channels.

保存条件：

2-8℃